Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Neuroradiology
Published in: Clinical Neuroradiology 2/2021

01-06-2021 | Magnetic Resonance Imaging | Original Article

Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance

Authors: Antonella Meloni, Domenico Montanaro, Daniele De Marchi, Mariachiara Resta, Petra Keilberg, Laura Pistoia, Vincenzo Positano, Anna Spasiano, Tommaso Casini, Caterina Cinzia De Bari, Sara De Cori, Alessia Pepe

Published in: Clinical Neuroradiology | Issue 2/2021

Login to get access

Abstract

Purpose

A prospective study was conducted to evaluate signal changes in the dentate nucleus, globus pallidus, pons, and thalamus (normalized to the deep cerebellum white matter) in T1-weighted magnetic resonance (MR) images after serial injections of gadobutrol in patients with thalassemia without neurological lesions.

Methods

In this study three groups were scanned at both 1.5 T and 3 T: 15 thalassemia patients transfused and chelated with ≥4 gadobutrol administrations at a high dose (0.2 mmol/kg per scan) for late gadolinium enhancement (LGE) cardiovascular MR, 8 thalassemia patients and 13 healthy subjects who had never received gadolinium-based contrast agents (GBCA).

Results

Signal intensity (SI) ratios at 1.5 T in all regions were comparable among the three groups and were not correlated with the number of gadobutrol administrations.
In healthy subjects SI ratios were significantly different among the 4 regions, being higher in the pallidus.
The SI ratios at 1.5 T were significantly higher and not correlated with SI ratios at 3 T or with iron overload in the same regions assessed by the T2* technique.

Conclusion

This article describes the lack of increased SI in T1-weighted MR images after repeated administration of gadobutrol for cardiovascular MR studies in a high-risk population (high dose per scan, iron overload that can facilitate the transmetalation of gadolinium) scanned at 3 T and 1.5 T.
Literature
1.
Claussen C, Laniado M, Kazner E, Schörner W, Felix R. Application of contrast agents in CT and MRI (NMR): their potential in imaging of brain tumors. Neuroradiology. 1985;27:164–71.PubMed
2.
Niendorf HP, Felix R, Laniado M, Schörner W, Claussen C, Weinmann HJ. Gadolinium-DTPA: a new contrast agent for magnetic resonance imaging. Radiat Med. 1985;3:7–12.PubMed
3.
Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.PubMed
4.
Bruder O, Wagner A, Lombardi M, Schwitter J, van Rossum A, Pilz G, et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson. 2013;15:9.PubMedPubMedCentral
5.
Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8.PubMed
6.
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–62.PubMed
7.
Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817–28.PubMed
8.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–41.PubMed
9.
Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685–90.PubMed
10.
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228–32.PubMed
11.
Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470–2.PubMed
12.
Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783–91.PubMed
13.
Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, et al. High signal intensity in globus pallidus and dentate nucleus on Unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology. 2015;276:836–44.PubMed
14.
Weberling LD, Kieslich PJ, Kickingereder P, Wick W, Bendszus M, Schlemmer HP, et al. Increased signal intensity in the dentate nucleus on Unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743–8.PubMed
15.
Adin ME, Kleinberg L, Vaidya D, Zan E, Mirbagheri S, Yousem DM. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol. 2015;36:1859–65.PubMedPubMedCentral
16.
Cao Y, Huang DQ, Shih G, Prince MR. Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol. 2016;206:414–9.PubMed
17.
Ramalho J, Semelka RC, AlObaidy M, Ramalho M, Nunes RH, Castillo M. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. Eur Radiol. 2016;26:4080–8.PubMed
18.
Schlemm L, Chien C, Bellmann-Strobl J, Dörr J, Wuerfel J, Brandt AU, et al. Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Mult Scler. 2017;23:963–72.PubMed
19.
Tanaka M, Nakahara K, Kinoshita M. Increased signal intensity in the dentate nucleus of patients with multiple sclerosis in comparison with neuromyelitis optica spectrum disorder after multiple doses of gadolinium contrast. Eur Neurol. 2016;75:195–8.PubMed
20.
Zhang Y, Cao Y, Shih GL, Hecht EM, Prince MR. Extent of signal hyperintensity on Unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology. 2016;282:516–25.PubMed
21.
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805–10.PubMed
22.
Eisele P, Alonso A, Szabo K, Ebert A, Ong M, Schoenberg SO, et al. Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: An observational study. Medicine. 2016;95:e4624.PubMedPubMedCentral
23.
Yoo RE, Sohn CH, Kang KM, Yun TJ, Choi SH, Kim JH, et al. Evaluation of gadolinium retention after serial administrations of a macrocyclic gadolinium-based contrast agent (Gadobutrol): a single-institution experience with 189 patients. Invest Radiol. 2018;53:20–5.PubMed
24.
Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Hattingen E. Brain relaxometry after macrocyclic Gd-based contrast agent. Clin Neuroradiol. 2017;27:459–68.PubMed
25.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–82.PubMed
26.
Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51:447–53.PubMed
27.
Ramalho J, Ramalho M, AlObaidy M, Semelka RC. Technical aspects of MRI signal change quantification after gadolinium-based contrast agents’ administration. Magn Reson Imaging. 2016;34:1355–8.PubMed
28.
Meloni A, Ramazzotti A, Positano V, Salvatori C, Mangione M, Marcheschi P, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009;78:503–12.PubMed
29.
Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, et al. Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009;30:62–8.PubMed
30.
Meloni A, Favilli B, Positano V, Cianciulli P, Filosa A, Quarta A, et al. Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopaties. Haematologica. 2009;94:1625–7.PubMedPubMedCentral
31.
Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart. 2009;95:1688–93.PubMed
32.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.PubMed
33.
Quattrocchi CC, Ramalho J, van der Molen AJ, Rovira À, Radbruch A; GREC, European Gadolinium Retention Evaluation Consortium and the ESNR, European Society of Neuroradiology. Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement. Eur Radiol. 2019;29:3959–67.PubMed
34.
Positano V, Pepe A, Santarelli MF, Scattini B, De Marchi D, Ramazzotti A, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed. 2007;20:578–90.PubMed
35.
Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26:807–15.PubMed
36.
Kromrey ML, Liedtke KR, Ittermann T, Langner S, Kirsch M, Weitschies W, et al. Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years. Eur Radiol. 2017;27:772–7.PubMed
37.
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53.
38.
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002.PubMed
39.
Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991;9:409–15.PubMed
40.
Akhlaghpoor S, Ghahari A, Morteza A, Khalilzadeh O, Shakourirad A, Alinaghizadeh MR. Quantitative T2* magnetic resonance imaging for evaluation of iron deposition in the brain of beta-thalassemia patients. Clin Neuroradiol. 2012;22:211–7.PubMed
41.
Metafratzi Z, Argyropoulou MI, Kiortsis DN, Tsampoulas C, Chaliassos N, Efremidis SC. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol. 2001;74:407–10.PubMed
42.
Douthat WG, Acuña Aguerre G, Fernández Martín JL, Mouzo R, Cannata Andía JB. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration. Nephrol Dial Transplant. 1994;9:1431–4.PubMed
43.
Amiri A, Fatemi SJ, Fatemi SN. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats. Biometals. 2007;20:159–63.PubMed
44.
Kontoghiorghes GJ. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst. 1995;120:845–51.PubMed
45.
Fatemi SJ, Khajoee Nejad F, Zandevakili T, Dahoee Balooch F. Chelation of cobalt by combining deferasirox, deferiprone and desferrioxamine in rats. Toxin Rev. 2013;33:146–50.
46.
Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D. Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology. 2016;281:418–26.PubMed
47.
Lancelot E, Raynaud JS, Ferrari N, Desche P. Hepatic gadolinium deposition in pediatric hematopoietic stem cell transplant recipients. Radiology. 2016;281:982–3.PubMed
Metadata
Title
Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance
Authors
Antonella Meloni
Domenico Montanaro
Daniele De Marchi
Mariachiara Resta
Petra Keilberg
Laura Pistoia
Vincenzo Positano
Anna Spasiano
Tommaso Casini
Caterina Cinzia De Bari
Sara De Cori
Alessia Pepe
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
Clinical Neuroradiology / Issue 2/2021
Print ISSN: 1869-1439
Electronic ISSN: 1869-1447
DOI
https://doi.org/10.1007/s00062-020-00897-z

Other articles of this Issue 2/2021

Clinical Neuroradiology 2/2021 Go to the issue

Original Article

Solitaire Stentectomy Using a Stent-Retriever Technique in a Porcine Model

Correspondence

Multimodality Imaging Evaluation of an Uncommon Benign Nasal Cavity Tumor

Original Article

Differences in Safety and Efficacy of Endovascular Treatment for Acute Ischemic Stroke

Review Article

Cervical Carotid Plaque MRI

Original Article

Long-term Kinetic Papilledema Improvement After Venous Sinus Stenting in Idiopathic Intracranial Hypertension

Original Article

Coiling of the Internal Carotid Artery is Associated with Hypertension in Patients Suspected of Stroke